Episode
Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
- Podcast
- Business Of Biotech
- Published
- Mar 23, 2026
- Duration seconds
- 3057
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ...